Treatment of stress-induced skin disease by corticotropin releas

Details Treatment of stress-induced skin disease by corticotropin releas Treatment of stress-induced skin disease by corticotropin releas

1996-08-06

2000-02-01

Fay, Zohreh

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514456, 514653, A61K 3700, A61K 3135

Patent

active

060203056

ABSTRACT:
A method of reducing or blocking a stress-related atopic skin disease such as exzema or uticaria in a subject comprising administering to the patient an agent that antagonizes CRH-induced activation of skin mast cells, the agent being used alone or together with a second agent that inhibits activation of skin mast cells. Such agents include compositions that reduce the production or secretion of CRH, neurotensin or somatostatin or an agent that inhibitos the physiological action of CRH, neurotensin or somostatin on skin mast cells. The effects of CRH on skin mast cells can also be inhibited by histamine-3 receptor antagonists and by inhibitors of the phosphorylation of skin mast cell moesin.

REFERENCES:
Shapiro et al. Pharmacotherapy 5(3): 156-170 (1985).
Webster et al. Endocrinology 137(12): 5747-5750 (1996).
Tauberg et al. Anesthesia Progress XXX(6): 199-200 (1983).
Koblenzer Psychodermatology 14(3): 447-455 (1996).

Affiliated with

Also associated with

Rating

Treatment of stress-induced skin disease by corticotropin releas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of stress-induced skin disease by corticotropin releas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of stress-induced skin disease by corticotropin releas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-937556